IVVD
NASD Invivyd, Inc.$0.8663 ↑ +0.0271 (+3.23%) Trading Up from the previous close of $0.8392
- YTD change
- -64.93%
- vs 20-day SMA
- +1.23%
- vs 200-day SMA
- -35.46%
Price ranges
Price & Performance
-0.46 (-35.45%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 83.3% away from all-time highs of $5.1950
- IVVD is down 65% since the beginning of the year
- IVVD is down 39% over the past 12 months
- IVVD is up 5% over the past 1 month
- 11% of all IVVD investors are betting against IVVD
IVVD reads neutral: price sits above one of the two key moving averages, the 12-month move is -40.9%.
- Previous minute
- +$0.0000
- Last hour
- +$0.0166
- Last 5 days
- -8.81%
- vs 8-day SMA
- -0.93%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Invivyd, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers ADG20, a monoclonal antibody, targeting the spike protein of SARS-CoV-2 and related coronaviruses. The company was founded by Tillman U. Gerngross, Ren Russo and Laura Walker on June 3, 2020 and is headquartered in New Haven, CT.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
